An open-label multicentric study of the tolerability and response to escitalopram treatment in Indian patients with major depressive disorder.
J Indian Med Assoc
;
2007 Jul; 105(7): 364, 366, 368 passim
Article
in English
| IMSEAR
| ID: sea-97760
ABSTRACT
To evaluate the tolerability and response to escitalopram in Indian patients with major depression, over an 8-week open-label multicentric study was carried out among 18-65 years old Indian patients suffering from DSM IV major depressive disorder with Montgomery-Asberg depression rating scale (MADRS) total score> or =22. Patients received a fixed dose of escitalopram 10 mg daily for 2 weeks, followed by flexible dose of 10 to 20 mg daily for 6 weeks. Patients were evaluated for depression and rated on MADRS score and clinical global impressions-severity (CGI-S) and--improvement (CGI-I) scores. They were monitored for treatment-emergent adverse effects. A total of 119 patients were enrolled and 103 completed the trial. There was a decrease from baseline in the MADRS total score after one week of treatment continuing until 8 weeks. By week 8, 76.9% patients had responded to treatment (> or =50% or more reduction of MADRS total score). A similar pattern of improvement to that seen with the MADRS total score was seen with CGI-S and CGI-I scores. Escitalopram was well tolerated, with only 2 patients (1.7%) withdrawing from the study due to adverse events. There were no serious adverse events.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Main subject:
Psychological Tests
/
Psychometrics
/
Aged
/
Female
/
Humans
/
Male
/
Citalopram
/
Adolescent
/
Antidepressive Agents, Second-Generation
/
Adult
Type of study:
Controlled clinical trial
Language:
English
Journal:
J Indian Med Assoc
Year:
2007
Type:
Article
Similar
MEDLINE
...
LILACS
LIS